Skip to content
Deacon Keith Fournier Hi readers, it seems you use Catholic Online a lot; that's great! It's a little awkward to ask, but we need your help. If you have already donated, we sincerely thank you. We're not salespeople, but we depend on donations averaging $14.76 and fewer than 1% of readers give. If you donate just $5.00, the price of your coffee, Catholic Online School could keep thriving. Thank you. Help Now >

New drugs may hold the key to melanoma treatment

Free World Class Education
FREE Catholic Classes
Two drugs show remarkable survival rates in those suffering from the cancer

Two new drugs may provide an exciting and striking treatment option for those who suffer from advanced cases of melanoma.

We ask you, humbly: don't scroll away.

Hi readers, it seems you use Catholic Online a lot; that's great! It's a little awkward to ask, but we need your help. If you have already donated, we sincerely thank you. We're not salespeople, but we depend on donations averaging $14.76 and fewer than 1% of readers give. If you donate just $5.00, the price of your coffee, Catholic Online School could keep thriving. Thank you.

Help Now >

Highlights

By Catholic Online (NEWS CONSORTIUM)
Catholic Online (https://www.catholic.org)
6/3/2014 (9 years ago)

Published in Health

Keywords: News, Science, Medicine

LOS ANGELES, CA (Catholic Online) - In separate international trials, new drugs pembrolizumab and nivolumab, have seen great success treating melanoma, which is the most dangerous type of skin cancer, and also causes the most amount of deaths of any skin disease. When melanoma spreads to other organs it is very difficult to treat, and, until a few years ago, average survival was around half a year.

Sometimes all you can do is pray for those who suffer from illness.

Both drugs are designed to help the immune system recognize and target cancerous cells by blocking the biological pathway the cancers use to disguise themselves from the immune system.

Pembrolizumab, formerly known as MK-3475, was tested on 411 patients, of which 69% survived for at least one year. This drug is also being tested on cancers which utilize a similar method to block attacks from the immune system.

"Pembrolizumab looks like it has potential to be a paradigm shift for cancer therapy," said Dr. David Chao, consultant oncologist at the Royal Free London NHS Foundation Trust. Chao is conducting trials on melanoma and lung cancer patients.

64-year-old Warwick Steele has been receiving infusions of the drug every three weeks since October, and has seen phenomenal results.

"I got tired simply standing up and was literally too exhausted to shave. But now I feel back to normal and can do gardening and go shopping," he said.

Prior to his treatment, Steele could barely walk because the cancers in his lungs made it hard to breath. Scans have shown that just after three infusions, the cancer seems to have been totally cleared out of his lungs.

Nivolumab, which was tested in conjunction with the existing immunotherapy ipilimumab, saw 85% of its' 53 patients survive past a year, and 79% after two years.

---


'Help Give every Student and Teacher FREE resources for a world-class Moral Catholic Education'


Copyright 2021 - Distributed by Catholic Online

Join the Movement
When you sign up below, you don't just join an email list - you're joining an entire movement for Free world class Catholic education.

Lent logo
Saint of the Day logo

We ask you, humbly: don't scroll away.

Hi readers, it seems you use Catholic Online a lot; that's great! It's a little awkward to ask, but we need your help. If you have already donated, we sincerely thank you. We're not salespeople, but we depend on donations averaging $14.76 and fewer than 1% of readers give. If you donate just $5.00, the price of your coffee, Catholic Online School could keep thriving. Thank you.

Help Now >

Catholic Online Logo

Copyright 2024 Catholic Online. All materials contained on this site, whether written, audible or visual are the exclusive property of Catholic Online and are protected under U.S. and International copyright laws, © Copyright 2024 Catholic Online. Any unauthorized use, without prior written consent of Catholic Online is strictly forbidden and prohibited.

Catholic Online is a Project of Your Catholic Voice Foundation, a Not-for-Profit Corporation. Your Catholic Voice Foundation has been granted a recognition of tax exemption under Section 501(c)(3) of the Internal Revenue Code. Federal Tax Identification Number: 81-0596847. Your gift is tax-deductible as allowed by law.